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Abstract
Background: Chronic kidney disease (CKD) is common, and associated with increased risk of cardiovascular disease and
end-stage renal disease, which are potentially preventable through early identification and treatment of individuals at risk.
Although risk factors for occurrence and progression of CKD have been identified, their utility for CKD risk stratification
through prediction models remains unclear. We critically assessed risk models to predict CKD and its progression, and
evaluated their suitability for clinical use.
Methods and Findings: We systematically searched MEDLINE and Embase (1 January 1980 to 20 June 2012). Dual review
was conducted to identify studies that reported on the development, validation, or impact assessment of a model
constructed to predict the occurrence/presence of CKD or progression to advanced stages. Data were extracted on study
characteristics, risk predictors, discrimination, calibration, and reclassification performance of models, as well as validation
and impact analyses. We included 26 publications reporting on 30 CKD occurrence prediction risk scores and 17 CKD
progression prediction risk scores. The vast majority of CKD risk models had acceptable-to-good discriminatory performance
(area under the receiver operating characteristic curve.0.70) in the derivation sample. Calibration was less commonly
assessed, but overall was found to be acceptable. Only eight CKD occurrence and five CKD progression risk models have
been externally validated, displaying modest-to-acceptable discrimination. Whether novel biomarkers of CKD (circulatory or
genetic) can improve prediction largely remains unclear, and impact studies of CKD prediction models have not yet been
conducted. Limitations of risk models include the lack of ethnic diversity in derivation samples, and the scarcity of validation
studies. The review is limited by the lack of an agreed-on system for rating prediction models, and the difficulty of assessing
publication bias.
Conclusions: The development and clinical application of renal risk scores is in its infancy; however, the discriminatory
performance of existing tools is acceptable. The effect of using these models in practice is still to be explored.
Please see later in the article for the Editors’ Summary.
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Introduction
Chronic kidney disease (CKD) is increasingly common in the
US and worldwide [1,2]. Related complications, including end-
stage renal disease (ESRD) and cardiovascular disease (CVD),
have major public health and economic implications [1–3].
Screening for CKD has been somewhat controversial in the
absence of direct evidence from a randomized clinical trial [4].
However, early identification of individuals with CKD, especially
targeting populations with a high risk for CKD and related
adverse outcomes [5], followed by the implementation of
evidence-based interventions can slow or prevent the progression
to advanced stages of the disease, reduce the risk of CVD and
other complications of decreased glomerular filtration rate (GFR),
and improve survival and quality of life [6]. However, large
proportions of individuals with CKD remain undiagnosed and, as
a consequence, are not benefiting from those interventions. For
instance, in the US, awareness of CKD in the general population
remains very low [1]. During the 1999–2004 period, the
proportion of US adults with stage 3 CKD who reported being
aware of their status was only 11.6% in men and 5.5% in women.
Even among men with stage 3 CKD and elevated albuminuria,
awareness of weak or failing kidneys was only 22.8%. Among
those with stage 4 CKD, the corresponding percentage was 42%
for both men and women [1]. In clinical settings, awareness levels
are also low. Data from the US National Kidney Foundation’s
Kidney Early Evaluation Program, for the 2000–2009 period,
indicate that only 9% of patients with CKD are aware of their
diagnosis [7].
Strategies for early identification and treatment of people with
CKD are therefore needed worldwide. The use of complex and
potentially expensive detection strategies may prevent those at risk
from deriving the benefits of preventative interventions, especially
in settings where renal replacement therapy is not readily
available. Several risk factors that are independently associated
with the occurrence of CKD and easily assessable in routine
clinical settings have been incorporated in model equations for
predicting the occurrence of CKD or progression in people
already diagnosed with CKD. These models have utility even in
the context of automatic reporting of the estimated GFR (eGFR).
Indeed, recent data indicate that referral to a nephrologist by
primary care physicians as the result of making eGFR available
mostly occurs for certain subgroups in the population (women and
elderly), and a high proportion of referrals are inappropriate [8].
The use of risk models is very attractive and likely cost-effective
for large-scale CKD risk stratification, and would allow the
identification of all the segments of the population that would
benefit the most from CKD detection. To this end, it is very
important that existing models are not methodologically flawed,
and that they provide accurate estimates of the CKD risk in
different populations.
To date, there has been no effort, to our knowledge, to provide
decision makers and healthcare providers with a balanced account
of the performance of existing CKD risk models. We therefore
systematically reviewed studies of risk equations to predict CKD or
its progression, with the objectives of summarizing evidence on
their performance and exploring methodological issues surround-
ing their development and validation and application.
Methods
We performed literature searches to identify all risk models
developed to predict the presence/occurrence of CKD, or to
predict the progression of CKD in those with the disease. We also
searched for all studies that applied existing CKD risk models
either in the population from which the model was developed or in
different populations, and, lastly, we searched for all impact studies
and clinical practice guidelines that incorporated existing CKD
risk models.
Model Development and Validation Studies
Data sources and search strategy. We searched the
PubMed MEDLINE and Embase databases from 1 January
1980 to 20 June 2012, for English- or French- language studies of
CKD risk prediction model development and/or validation. We
used a combination of search terms related to CKD and
prediction. The search strategies are provided in detail in Texts
S2 and S3. In addition, we manually searched the reference lists of
eligible studies and relevant reviews, and traced studies that had
cited them through the ISI Web of Science to find additional
published and unpublished data.
Study selection. Two evaluators (J. B. E. and A. P. K.)
independently identified articles and sequentially screened them
for inclusion (Figure 1). Where necessary, the full text of articles
and/or supplemental materials (tables and appendices) was
reviewed before deciding on inclusion. Disagreements were solved
by consensus between both authors.
Eligible articles had to report a risk assessment tool (equation
and/or score) for predicting CKD or its progression, derived in
adult human populations. Reporting of quantitative measures of
the performance of tools was preferable, but not necessary for
inclusion. The reported metrics of evaluation of predictive ability
could be the area under the receiver operating characteristic curve
(AUC) or C-statistic, reclassification percentage, net reclassifica-
tion improvement (NRI), or integrated discrimination improve-
ment index (IDI). These metrics are recognized and used for the
assessment of prediction models [9,10]. We excluded studies that
reported only measures of association between risk factors and
CKD without information on the beta coefficients of variables
included in a prediction equation, and simulation studies.
Data extraction and quality assessment. Two reviewers
(J. B. E. and A. P. K.) independently conducted the data extraction
and quality assessment. We did not use a particular framework for
quality assessment, as there is no consensus on a quality assessment
framework for risk prediction models. Consequently, we did not
develop a formal protocol for the review (Text S1). From each
study, we extracted data on study design, setting, population
characteristics, the number of patients in the derivation and
validation cohorts, the number of participants with the outcome of
interest, the number of candidate variables tested as predictors,
and the number and list of those variables included in the final
model, as well as the type of statistical model used. For the
discriminative performance of models, we extracted information
on the AUC or C-statistic, which indicates the ability of a risk
model to rank-order individuals’ risks. To describe model
calibration, we extracted data on the difference between the
observed and predicted rates of CKD, as well as the p-value of the
corresponding test statistic. Measures of calibration assess the
ability of a risk prediction model to predict accurately the absolute
level of risk that is subsequently observed.
For the assessment of reclassification, we extracted the NRI
and IDI values, and the accompanying 95% CIs and p-values,
when available. Reclassification analyses generally indicate the
proportion of individuals who are reclassified from one risk
stratum (based on estimated risk provided from a first model) to a
different risk stratum (based on estimated risk from a different
Overview of CKD Risk Prediction Models
PLOS Medicine | www.plosmedicine.org 2 November 2012 | Volume 9 | Issue 11 | e1001344
model, or a model that has additional variables compared with
the first model). The IDI measures the extent to which the use of
a new risk marker correctly revises upward the predicted risk of
individuals who experienced the event of interest and correctly
revises downward the predicted risk of individuals who did not
experience the event.
Data synthesis. Given the wide range of metrics used for
the assessment of the predictive ability of CKD risk models, and
the heterogeneity in both the risk factors used for prediction
and their number, as well as the study designs, we opted to
conduct a narrative synthesis of the evidence instead of a meta-
analysis.
Figure 1. Article selection process.
doi:10.1371/journal.pmed.1001344.g001
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Impact Studies and Implementation of Risk Models in
Guidelines
Impact studies were captured by (1) scanning those publications
identified through the search strategy for model development and
validation, and (2) applying the search strategy for impact studies
proposed by Reilly and Evans [11], which combines the model’s
acronym, name of the cohort, or first author with a specific search
term (Text S3). We searched relevant clinical practice guidelines to
investigate the implementation of CKD prediction models in
countries in which such models have been developed. In the
absence of validated strategies for these types of searches, we
targeted guidelines (when available in English language) compiled
by a selection of organizations known to be involved in issues
relating to kidney diseases, including the American Society of
Nephrology (http://www.asn-online.org), the US National Kidney
Foundation [12], the UK National Institute for Health and
Clinical Excellence [13], the International Society of Nephrology
[14], the European Renal Association–European Dialysis and
Transplant [15], the Canadian Society of Nephrology [16],
Kidney Disease: Improving Global Outcomes [17], The Korean
Society of Nephrology (http://www.ksn.or.kr/english/), the Jap-
anese Society for Dialysis Therapy [18], The Japan Association of
Chronic Kidney Disease Initiatives (J-CKDI) [19], and the
Taiwan Society of Nephrology [20].
Results
Figure 1 describes the study selection process. Of the citations
identified through searches, 210 abstracts were selected for in-
depth evaluation, and 46 full-text publications were reviewed.
After all exclusions, 26 articles, reporting on 30 CKD prediction
risk scores and 17 CKD progression risk scores, met the eligibility
criteria and were included in the review.
CKD Prediction Risk Scores
Table 1 summarizes data from studies that developed CKD risk
prediction models. Five of the 30 CKD risk prediction models
were developed using cross-sectional data (thus, prevalent CKD)
[21–24], and the remaining models were based on cohort studies.
Populations, outcomes, and risk factors. The majority of
the 30 CKD risk models were developed from samples that mostly
included white individuals, and only four studies included
exclusively Asian participants [23–26]. The number of participants
included in the studies ranged from 534 to 1.6 million, and their
ages ranged from 18 to 90 y. The length of follow-up in the cohort
studies ranged from 1 to 10 y.
The definition of CKD was fairly consistent across prediction
models (eGFR,60 ml/min/1.73 m2), although nine models
focused on predicting diabetic nephropathy [22], and another
on CKD prediction among HIV-positive individuals [26]. The
included risk models used the Modification of Diet in Renal
Disease (MDRD) Study equation to estimate GFR, with the
exception of models from the ADVANCE study [27], which used
estimates from the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation. The original MDRD equa-
tion is eGFR (ml/min/1.73 m2) = 1756standardized Scr (mg/
dl)21.1546age (y)20.20361.212 [if black]60.742 [if female], where
Scr is serum creatinine [28]. The less used CKD-EPI equation is
eGFR (ml/min/1.73 m2) = 1416min(Scr/k, 1)a6max(Scr/k,
1)21.2096 0.993age61.018 [if female]61.159 [if black], where Scr
is serum creatinine, k is 0.7 for females and 0.9 for males, a is
20.329 for females and 20.411 for males, min indicates the
minimum of Scr/k or 1, and max indicates the maximum of Scr/k
or 1 [29].
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Ten studies provided usable data on the numbers of candidate
variables tested for inclusion in the models. This number ranged
from one to 24, giving conservative estimates of the ratio of the
number of observed events (outcome of interest) to the number of
candidate variables ranging from six to 166. The predictors most
commonly included in the final prediction models were age, sex,
body mass index, diabetes status, systolic blood pressure, serum
creatinine, a measure of proteinuria, and serum albumin or total
protein (Table S1). Three studies used novel biomarkers or genetic
or circulating factors [22,30,31]. Eighteen models were derived
using logistic regressions, and three using Cox regressions. All
studies reported the original model with beta coefficients, and five
studies presented additional point-based scoring systems
[21,27,32], or risk calculators [33,34].
Performance of risk prediction models. Table 1 shows
the performance of the various CKD risk models. All the included
studies reported a C-statistic ranging from 0.57 to 0.88, indicating
a modest-to-good discriminatory performance. Nine risk scores
were internally validated, through split-sample validation in four
cases (three of these were also externally validated), and boot-
strapping in five other studies. Twelve risk models had an estimate
of calibration: Hosmer-Lemeshow test statistics in most cases,
which generally indicated good calibration.
CKD model improvement. Four studies assessed model
improvement subsequent to adding extra variables. One study
reported a significant improvement after adding circulating
biomarkers (aldosterone and homocysteine) to traditional CKD
risk factors [30]; the difference in AUC was 0.012 (p=0.00233),
NRI 6.9% (p=0.0004), and IDI 0.013 (p=0.004). The second
study reported an AUC difference of 0.001 (p=0.2) for adding
genotypic information (16 single nucleotide polymorphisms) to
known risk factors [31]. The third study reported no statistically
significant improvement from adding uric acid, postprandial
glucose, hemoglobin A1c, and proteinuria $ 100 mg/dl to
traditional risk factors, with nonsignificant differences in AUC
(20.003), NRI (20.0889), and IDI (0.0141) [25]. The last study
found that a model for predicting major renal events using eGFR
and albumin/creatinine ratio (ACR) (AUC: 0.818) was superior to
models with either of the predictors alone (AUC: 0.779 for eGFR,
and 0.752 for ACR); all three models were inferior to an expanded
model with five additional variables (AUC: 0.847) (all p,0.05 for
AUC comparison) [27]. In the same study, the eGFR+ACR
(AUC: 0.629) and ACR alone (AUC: 0.627) models had similar
performance for predicting new-onset albuminuria; both were
superior to the eGFR alone model (AUC: 0.543) (both p,0.05),
while all three were inferior to an extended model (AUC: 0.647)
with six extra variables (all p,0.05 for AUC comparison) [27].
Validation of CKD risk prediction models. Table 2 shows
the results of the external validation of CKD risk models. Only
eight of the models were externally validated. Of these, only four
models were validated more than once: twice for three models
[25,34–36] and three times for one model [21,37,38]. The AUC in
validation studies (0.57 to 0.88) was generally lower than that in
the derivation sample; the change from the original C-statistic
from when the model was first derived ranged from 20.2 to +0.06
(Table 2), being negative or null except in two cases of validation
of one score where it was positive [25], thus indicating a generally
lower discrimination in validation populations. In the validation
populations, the calibration was also poorer, though it was not
assessed in most of validation studies.
Risk Scores for Predicting Progression of CKD to ESRD
Table 3 shows the models for the prediction of progression to
later stages among people with already established CKD. We
found 17 CKD progression risk scores, developed from Cox
regression models using data from clinical settings, mainly in
white populations. Two of the CKD progression risk scores were
developed from a cohort of people with type 2 diabetes and
nephropathy [39,40], and three other scores used cohorts of
people exclusively with IgA nephropathy [41–43]. The risk
factors included in CKD progression risk models varied. The
number of candidate variables tested for inclusion in the models
ranged from ten to 24, corresponding to a ratio of number of
observed events (outcome of interest) to number of candidate
variables of four to 16. For one risk model, the performance in
the derivation sample was not reported [39], although the
performance of the score was later assessed in a validation study
conducted in a different population. When evaluated, the C-
statistic of these models ranged from 0.56 to 0.94, and
calibration (reported for two models only) was good. In addition
to reporting beta coefficients for regression models, four studies
also provided a point-based scoring system [42–44] or a risk
calculator [45].
As shown in Table 4, five of the CKD progression risk models
were externally validated (C-statistic: 0.83 to 0.91); the change in
C-statistic from the original value when the model was first
developed ranged from 20.1 to +0.03. This change was negative
in all but one case, thus indicating a generally poorer discrimi-
nation.
Two studies investigated the improvement of three different
CKD progression models [33,40], after adding biomarkers to
traditional risk factors (serum bicarbonate and phosphate in one
case [33], and Troponin T plus brain natriuretic peptide in the
two other cases) [40]. The change in C-statistic or AUC varied
from 0.01 to 0.02, and NRI from 16.9% to 26.7%.
Impact Studies and Incorporation of CKD Prediction
Models in Clinical Practice Guidelines
We found no evidence in guidelines of recommendations for
using CKD risk prediction models to estimate the risk in patients
either in clinical or community settings. We also did not find any
studies assessing the impact of adopting CKD (occurrence and
progression) risk scores in clinical practice on the process of care
and outcomes of patients.
Discussion
This systematic review shows that a sizeable number of renal
risk prediction models have been developed, with, however,
variation in their quality. Reasons for this may be specific to
nephrology, where risk prediction is still in its infancy and the
methodology for predictive research may be underappreciated.
Despite the heterogeneity of CKD, with several specific forms, this
review demonstrates the feasibility of defining individual renal risk
using a combination of commonly assessed variables. Indeed, there
was remarkable similarity between the variables that entered the
prediction models (Tables S1 and S2), each developed in a distinct
group of participants, sometimes with specific forms of CKD. The
discriminative performance of existing models was generally
acceptable-to-good on the derivation sample. However, when
corrected for overfitting (internal validation) or tested in a new
population (external validation), this discriminative performance
was modest-to-acceptable. For CKD risk prediction, the
SCORED model appears to be the most reliable, as it is the most
externally validated model, with a reasonable discrimination [21].
Regarding CKD progression, no risk model has been extensively
validated in different populations.
Overview of CKD Risk Prediction Models
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Potential Public Health and Clinical Applications of CKD
Risk Models
Risk prediction models have potential applications in the
prevention and management of CKD. Risk communication to
patients may motivate them for lifestyle modification and
adherence to prescribed therapies. Using models for predicting
progression of CKD, clinicians may be able to tailor disease-
modifying therapies as well as frequency of monitoring to
individual risk. Indeed, therapies for controlling several variables
included in CKD progression models (e.g., diabetes and hyper-
tension) have been shown to delay CKD progression. Further-
more, using CKD progression models to identify patients who are
most likely to need renal replacement therapy would allow patient
education on available therapeutic options. CKD risk scores may
be useful in the assessment of novel technologies or biomarkers for
risk prediction, or for patient recruitment in prevention trials.
They can also serve in mass screening and public education
initiatives. For all these applications, estimates of CKD risk from
prediction models must be accurate and validated.
Development of Existing CKD Risk Prediction Models
The performance of prediction models is largely determined by
the appropriateness of the methodological approaches used to
develop them. Virtually none of the existing CKD models was
developed using data specifically collected for risk modeling
purposes. This may raise concerns about the quality of the
predictors and outcomes tested/included in the models, as well as
the completeness of measurements. Lessons learned from CVD
prediction suggest that the source of data for model development
matters less, provided that the ensuing model can reliably predict
the outcome of interest in different populations [46]. Indeed, in
practice, assembling data only for the purpose of modeling can be
challenging, and researchers tend to rely on available data
collected for other reasons [9]. At least four of the models were
likely statistically underpowered, based on having a ratio of the
number of outcomes to the number of candidate predictors of ,8
[24,26,40,41,47]. The performance of such models tends to drop
substantially when the model is applied to different populations
[24]. Other mistakes that affect model performance were present
across studies, including dichotomization of continuous variables
prior to modeling, linearity assumptions without formal testing,
and exclusion of participants with missing values on predictor/
outcome variables.
Internal Validation of Existing CKD Prediction Models
One model was published without indicators of performance
during the derivation process [39]. Most models provided
measures of performance, which were based on the direct
application of the model to the derivation sample (apparent
performance). This approach is optimistic (self-fulfilling prophecy).
Some models provided performance measures from internal split-
sample or bootstrap validation, which may provide the new user
with an idea about what to expect when applying the model to
different populations. When reported, discrimination was always
good for CKD progression models, and acceptable-to-good for
prevalent/incident CKD models, indicating that these models
were able to differentiate participants with CKD from those
without in the derivation sample. Calibration, a key property of
model performance, was less commonly assessed during the
derivation process. Whether calibration performance of a model in
one population can inform its behavior in another population is
still debated. However, there is a growing agreement that, because
calibration is largely affected by the background risk, which varies
across populations, models need to be updated through recalibra-
tion procedures to provide accurate estimates of the risk in new
populations. There have been attempts to update some of the
existing CKD models, but the procedures used (addition of extra
variables) have focused on improvement in discriminatory
performance [25,27,30,31], and only one study reported change
in the calibration properties [27].
External Validation of Existing CKD Risk Prediction
Models
The demonstration of the performance of a model in new
populations is an important step before recommending its
widespread use. A limited number of existing CKD prediction
models have been tested on different populations [21,22,25,32–
35,45]. Validation studies have mainly been conducted by the
same group of investigators who developed the models. This is
methodologically inferior and quantitatively insufficient to provide
good indicators of models’ behavior in various populations. Hence,
more validation studies of existing models are needed, ideally by
different investigators, to guarantee their generalizability to a
larger number of people. Instead of developing new models for
their own setting, investigators in the field of CKD may consider
integrating aspects of the validation of existing models into future
studies. In addition to providing indicators of the performance of
existing models in various settings, such an approach limits
unnecessary development of new models.
Implementation of Existing CKD Prediction Models
CKD models have largely been published in the form of
mathematical equations, with point-scoring systems [21,32,42–44]
or calculators [33,34,45] for a few. The mathematical format may
not be suitable for application in various settings, particularly by
busy clinicians who may be less familiar with manipulating
complex formulas. Translation efforts are therefore needed to
convert accurate and validated CKD prediction equations into
simple tools that can improve their uptake in various settings [33].
Some context-specific efforts may also be required to derive
appropriate cutoffs for defining high-risk status when models are
integrated in guidelines for screening. It is, however, important to
confirm whether the implementation of CKD risk prediction
models affects the behavior of healthcare providers and improves
outcomes of care. At present, no implementation study of CKD
risk prediction models has been conducted.
Published studies have relied on GFR estimated from the
MDRD equation to define CKD [28]. The MDRD equation
provides less accurate estimates of GFR in different ethnic groups,
compared with estimates derived from the more recent CKD-EPI
equation [29], resulting in ‘‘over-diagnosis’’ of CKD using the
MDRD equation. There have been suggestions that this over-
diagnosis may have little effect on estimates of the association
between risk factors and CKD outcomes [24,32] and, accordingly,
on discriminatory performance when models developed to predict
the outcome of CKD based on the MDRD equation are applied to
the outcome of CKD based on the CKD-EPI formula. However,
the difference in prevalence/incidence of CKD based on the two
formulas will invite recalibration of MDRD equation–based
models to improve their applicability with the increasing
international adoption of CKD-EPI estimates of GFR for CKD
diagnosis.
Participants in the reviewed studies were overwhelmingly white.
A homogenous population does not allow researchers to probe
into the whole scope of the variability in CKD risk. This is even
more important for CKD than for other diseases, as some ethnic
groups are particularly prone to CKD (e.g., African-Americans),
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and the use of risk stratification tools in these groups may be more
warranted. Future studies should therefore incorporate more
participants of different ethnic backgrounds.
Strengths and Limitations of the Review
The strengths of this review include the exclusion of studies that
reported only effect estimates for independent association of risk
factors with CKD. These measures alone provide no information
on model calibration and global discriminative performance. The
case for predictive testing depends not merely on the magnitude of
the risk ratio, but also on the extent to which the test results are
useful for improving prediction of disease when various risk factors
are accounted for. This systematic review may also help policy
makers decide whether to incorporate risk tools in guidelines for
screening, routine evaluation, and management of CKD. Such an
inclusion may be premature at this point in time, particularly in
the absence of extensive external validation studies and impact
analyses. We did not explicitly rank or categorize the quality of
existing CKD risk models, mindful that there is no agreed-on
scientific system for rating risk prediction model quality. Some will
argue that minimizing risk for potential bias is of critical
importance, while others might support the view that a risk score
should be judged on its ability to perform accurately across diverse
settings. Finally, our ability to assess publication bias was limited.
Conclusion
This review suggests that risk models for predicting CKD or its
progression have a modest-to-acceptable discriminatory perfor-
mance, but would need to be better calibrated and externally
validated—and the impact of their use on outcomes assessed—
before these are incorporated in guidelines. Their potential
application for screening or management to identify CKD in a
heterogeneous population will also depend on the context. In the
US, for example, the adoption of the Kidney Disease Outcomes
Quality Initiative guidelines has led to systematic reporting of
eGFR by laboratories whenever serum creatinine is requested.
Consequently, a certain degree of de facto opportunistic CKD
screening is happening. In such a context, risk scores for predicting
CKD progression or outcomes would be particularly useful for
defining prognosis in identified people. However, an important
fraction of the population at high risk of CKD without access to
care could still be identified in the community using CKD risk
prediction tools.
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Editors’ Summary
Background. Chronic kidney disease (CKD)—the gradual
loss of kidney function—is increasingly common worldwide.
In the US, for example, about 26 million adults have CKD, and
millions more are at risk of developing the condition.
Throughout life, small structures called nephrons inside the
kidneys filter waste products and excess water from the
blood to make urine. If the nephrons stop working because
of injury or disease, the rate of blood filtration decreases, and
dangerous amounts of waste products such as creatinine
build up in the blood. Symptoms of CKD, which rarely occur
until the disease is very advanced, include tiredness, swollen
feet and ankles, puffiness around the eyes, and frequent
urination, especially at night. There is no cure for CKD, but
progression of the disease can be slowed by controlling high
blood pressure and diabetes, both of which cause CKD, and
by adopting a healthy lifestyle. The same interventions also
reduce the chances of CKD developing in the first place.
Why Was This Study Done? CKD is associated with an
increased risk of end-stage renal disease, which is treated
with dialysis or by kidney transplantation (renal replacement
therapies), and of cardiovascular disease. These life-threat-
ening complications are potentially preventable through
early identification and treatment of CKD, but most people
present with advanced disease. Early identification would be
particularly useful in developing countries, where renal
replacement therapies are not readily available and resourc-
es for treating cardiovascular problems are limited. One way
to identify people at risk of a disease is to use a ‘‘risk model.’’
Risk models are constructed by testing the ability of different
combinations of risk factors that are associated with a
specific disease to identify those individuals in a ‘‘derivation
sample’’ who have the disease. The model is then validated
on an independent group of people. In this systematic
review (a study that uses predefined criteria to identify all the
research on a given topic), the researchers critically assess
the ability of existing CKD risk models to predict the
occurrence of CKD and its progression, and evaluate their
suitability for clinical use.
What Did the Researchers Do and Find? The researchers
identified 26 publications reporting on 30 risk models for
CKD occurrence and 17 risk models for CKD progression that
met their predefined criteria. The risk factors most commonly
included in these models were age, sex, body mass index,
diabetes status, systolic blood pressure, serum creatinine,
protein in the urine, and serum albumin or total protein.
Nearly all the models had acceptable-to-good discriminatory
performance (a measure of how well a model separates
people who have a disease from people who do not have
the disease) in the derivation sample. Not all the models had
been calibrated (assessed for whether the average predicted
risk within a group matched the proportion that actually
developed the disease), but in those that had been assessed
calibration was good. Only eight CKD occurrence and five
CKD progression risk models had been externally validated;
discrimination in the validation samples was modest-to-
acceptable. Finally, very few studies had assessed whether
adding extra variables to CKD risk models (for example,
genetic markers) improved prediction, and none had
assessed the impact of adopting CKD risk models on the
clinical care and outcomes of patients.
What Do These Findings Mean? These findings suggest
that the development and clinical application of CKD risk
models is still in its infancy. Specifically, these findings
indicate that the existing models need to be better
calibrated and need to be externally validated in different
populations (most of the models were tested only in
predominantly white populations) before they are incorpo-
rated into guidelines. The impact of their use on clinical
outcomes also needs to be assessed before their widespread
use is recommended. Such research is worthwhile, however,
because of the potential public health and clinical applica-
tions of well-designed risk models for CKD. Such models
could be used to identify segments of the population that
would benefit most from screening for CKD, for example.
Moreover, risk communication to patients could motivate
them to adopt a healthy lifestyle and to adhere to prescribed
medications, and the use of models for predicting CKD
progression could help clinicians tailor disease-modifying
therapies to individual patient needs.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001344.
N This study is further discussed in a PLOS Medicine
Perspective by Maarten Taal
N The US National Kidney and Urologic Diseases Information
Clearinghouse provides information about all aspects of
kidney disease; the US National Kidney Disease Education
Program provides resources to help improve the under-
standing, detection, and management of kidney disease (in
English and Spanish)
N The UK National Health Service Choices website provides
information for patients on chronic kidney disease,
including some personal stories
N The US National Kidney Foundation, a not-for-profit
organization, provides information about chronic kidney
disease (in English and Spanish)
N The not-for-profit UK National Kidney Federation support
and information for patients with kidney disease and for
their carers, including a selection of patient experiences of
kidney disease
N World Kidney Day, a joint initiative between the Interna-
tional Society of Nephrology and the International
Federation of Kidney Foundations, aims to raise awareness
about kidneys and kidney disease
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